ERBB2 and cancer: This concept has contributed to the development of small molecules and monoclonal antibodies that stop uncontrolled cancer cell growth by: (1) interrupting oncogenic signals that are responsible for tumor growth and cell division (e.g., anti-HER2, anti-EGFR, and CDK4/6 inhibitors); (2) initiating programmed cancer cell death (e.g., PPARi and anti-bcl2); and (3) starving cancer cells by depriving them of the hormones/growth factors they need to grow (e.g., anti-estrogens and -androgens).